Accepted Manuscript

The vagus nerve in appetite regulation, mood and intestinal inflammation

Kirsteen N. Browning, Simon Verheijden, Guy E. Boeckxstaens

PII: S0016-5085(16)35487-7
DOI: 10.1053/j.gastro.2016.10.046
Reference: YGAST 60863

To appear in: Gastroenterology

Accepted Date: 27 October 2016

Please cite this article as: Browning KN, Verheijden S, Boeckxstaens GE, The vagus nerve in
appetite regulation, mood and intestinal inflammation, Gastroenterology (2017), doi: 10.1053/
j.gastro.2016.10.046.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
 ACCEPTED MANUSCRIPT

The vagus nerve in appetite regulation, mood and intestinal

inflammation

Kirsteen N. Browning1, Simon Verheijden2, Guy E. Boeckxstaens2,3,*

PT
1
Department of Neural and Behavioral Science

RI
Penn State College of Medicine

500 University Drive

SC
MC H109

Hershey, PA 17033

U
AN
Translational Research Center of Gastrointestinal Disorders (TARGID)

KU Leuven

Herestraat 49
M

3000 Leuven, Belgium

D

3
Division of Gastroenterology & Hepatology
TE

University Hospital Leuven

Herestraat 49
EP

3000 Leuven, Belgium

C

*Address of correspondence: Prof. dr. Guy Boeckxstaens, [email protected]

AC

Financial arrangements – conflicts of interest: none

Funding: GEB is supported by a European Research Council (ERC) Advanced Grant (ERC-
2013-Adg): 340101 Cholstim. SV is supported by a FWO postdoctoral research fellowship. KNB
is supported by a National Institutes of Health grant NIH NIDDK 078364 and National Science
Foundation grant NSF IOS1148978.

1
 ACCEPTED MANUSCRIPT

Abstract

Although the gastrointestinal (GI) tract contains intrinsic neural plexuses that allow a significant
degree of independent control over GI functions, the central nervous system provides extrinsic
neural inputs that modulate, regulate and integrate these functions. In particular, the vagus
nerve (VN) provides the parasympathetic innervation to the GI tract, co-ordinates the complex

PT
interactions between central and peripheral neural control mechanisms. This review will discuss
the physiological roles of the afferent (sensory) and motor (efferent) vagus in regulation of

RI
appetite, mood and the immune system, as well as the pathophysiological outcomes of VN
dysfunction resulting in obesity, mood disorders and inflammation. The therapeutic potential of

SC
VN modulation to attenuate or reverse these pathophysiological outcomes and restore
autonomic homeostasis will also be discussed.

U
AN
M
D
TE
C EP
AC

2
 ACCEPTED MANUSCRIPT

Introduction

The vagus nerve (VN), the longest cranial nerve in the body, not only regulates gut physiology,
but is also involved in controlling the cardiovascular, respiratory, immune and endocrine
systems. To date, its role in the regulation of appetite and obesity is increasingly recognized,
and involves a complex interplay between central and peripheral mechanisms involving both

PT
afferent and efferent VN fibers. Similarly, it is increasingly recognized that the VN communicates
with the immune system, i.e. inflammation in the periphery is detected by vagal afferents and

RI
integrated in the brainstem, affecting appetite, mood and sickness behavior generating,
ultimately, an efferent vagal signal modulating the immune response. The “great wandering

SC
protector” plays a crucial role in the organism homeostasis, and is currently being explored as
therapeutic target in a variety of disorders. Undoubtedly, the VN still hides many undiscovered
mysteries relevant for better understanding of physiology and pathophysiology and the

U
development of better treatments. In the present review, the current knowledge with respect to
AN
appetite regulation, mood and intestinal inflammation will be reviewed.
M

Vagal anatomy and neuroanatomy

Intrinsic neural networks within the gastrointestinal (GI) tract, including myenteric and
D

submucosal plexuses as well as interstitial cells of Cajal (ICC’s), allow a substantial degree of
TE

autonomy over GI functions such as motility, secretion and absorption1. The central nervous
system (CNS), however, provides extrinsic neural inputs which integrate, regulate, and
modulate these responses. The sympathetic nervous system provides a principally inhibitory
EP

influence over GI muscle and mucosal secretion and, at the same time, regulates GI blood flow
through neural-dependent vasoconstriction. The parasympathetic nervous system, in contrast,
C

provides both excitatory and inhibitory control over gastric, intestinal and pancreatic functions,
suggestive of a more complex homeostatic regulation (see 1 for review). The stomach and upper
AC

GI tract in particular receive an especially dense parasympathetic innervation, the density of

which decreases as one progresses distally through the intestine 2,3 .

The parasympathetic innervation to the GI tract and pancreas are provided by the VN.
As a mixed sensory-motor nerve, the vagus contains approximately 70-80% sensory fibers,
depending on the species4. The cell bodies of these pseudounipolar sensory neurons are
located in the paired nodose ganglia (inferior ganglion of the VN) located in the transverse

3
 ACCEPTED MANUSCRIPT

process of the first cervical vertebra, although some cell bodies in the jugular (superior) ganglion
may provide innervation to the GI tract. GI vagal afferents are principally unmyelinated C- or
thinly myelinated Aδ-fibers and are classified based upon the location of their receptive field
(mucosa, muscle or serosa-mesenteric), the region of GI tract innervated, primary stimulus
modality (chemical, osmotic, mechanical), or their response to distention or pressure5. The

PT
majority of vagal afferents are sensitive to low pressure distention, although some vagal
afferents can respond to high distention pressures; while the majority of GI vagal afferents traffic

RI
is interoceptive, therefore it is also likely that they play a role in nociception, or in the emotional-
affective response to pain6.

SC
The central terminals of vagal afferents enter the brainstem via the tractus solitarius
(TS), and synapse onto neurons of the nucleus of the tractus solitarius (NTS) using glutamate
as their principle neurotransmitter7. Some vagal afferents also make monosynaptic connections

U
within the dorsal motor nucleus of the vagus (DMV)8, or with neurons of the area postrema
AN
(AP)9. Together, the NTS, DMV and AP, known as the dorsal vagal complex (DVC), function as
a critical intersection in the integration of ascending interoceptive signals with descending
visceromotor signals. The entire DVC area, which lies ventral to the 4th ventricle, is highly
M

vascularized with fenestrated capillaries and is essentially a circumventricular organ10. An

additional layer of subependymal cerebrospinal contacting neurons (CSF-cNs) are positioned
D

between the CSF and DVC neurons and may integrate the detection of circulating signals with
the modulation of autonomic, including GI, functions11.
TE

The NTS appears organized in a viscerotopic manner according to the region of afferent
12
input . NTS neurons integrate the vast volume of sensory information together with inputs
EP

received from other brainstem and higher CNS nuclei involved in autonomic homeostatic
regulation (see later). The integrated response is then relayed to the adjacent DMV which
C

contains the preganglionic parasympathetic motor neurons that send the output response back
to the viscera via the efferent VN. The NTS-DMV synapse uses glutamate, GABA or
AC

catecholamines as neurotransmitters, although evidence from several groups suggests that,

under experimental conditions, GABA is the predominant neurotransmitter13–15. Vagal efferent
outflow to the viscera, therefore, appears to be under a tonic inhibitory influence. Dendritic
projections of NTS and DMV neurons intermingle within the various subnuclei, however,
possibly providing a means by which autonomic reflexes may be integrated across organ
system16.

4
 ACCEPTED MANUSCRIPT

Unlike the NTS, the DMV does not display a viscerotopic or organotopic organization.
Instead, DMV neurons are organized in spindle-shaped ‘columns’ that extend throughout the
rostro-caudal extent of the nucleus and innervate the GI tract via one of the five
subdiaphragmatic vagal branches17. In humans, the DMV can be subdivided into nine distinct
subnuclei with six distinct morphological and neurochemical neuronal phenotypes18. Most GI

PT
regions receive innervation from more than one subdiaphragmatic vagal branch, however; the
stomach is innervated by the anterior and posterior gastric branches as well as the hepatic
branch, the duodenum is innervated by all vagal branches, and the colon is innervated by both

RI
the celiac and accessory celiac branches3. In humans, the vagus innervates the right two-thirds
of the transverse colon, with parasympathetic innervation to the left third of the transverse colon,

SC
the descending colon and rectum arising from the pelvic nerves19. Early neuronal tracing
studies showed vagal efferent fibers were present within the celiac ganglion20 suggesting a role

U
in the modulation of splenic nerves and a potential anatomical basis for the cholinergic anti-
inflammatory pathway (CAIP). The use of the trans-synaptic, pseudorabies virus (PRV), to map
AN
the central neurocircuits innervating the spleen did not, however, find labeling in the DMV21.
Vagal nerve stimulation clearly modulates splenic function (see later), but the anatomical and
mechanistic basis of this action has yet to be clarified. For the purposes of this review, the
M

principle CNS areas and inputs involved in the modulation of GI vagal reflexes by diet,
inflammation and mood disorders are outlined in Table 1.
D
TE

Effects of diet and obesity on vago-vagal functions

EP

The GI tract is one of several organs that contribute to the peripheral signaling of food
intake and satiety and, increasingly, vagally-mediated reflexes are recognized as being critical
to the neural control of energy homeostasis22 particularly the short-term (homeostatic), rather
C

than longer-term (hedonic), control of appetite and food intake, although clearly the two
pathways are inter-related and dependent23.
AC

Gastric distention activates vagal afferent mechanoreceptors in a dose-dependent

manner, suggesting that some mechanosensitive afferents control meal size via signaling of
volume or load. In contrast, chemosensitive vagal afferents are activated in response to luminal
pH, osmolality, and chemical stimulation, although they can also be activated by light stroking or
compression of the mucosa5. Mucosal afferents are most abundant in the upper small intestine,

5
 ACCEPTED MANUSCRIPT

where they innervate the mucosal villae or crypts24. Afferent terminals are found in close
proximity to mucosal enteroendocrine cells24 and respond to the mediators they release. Over
30 GI neurohormones have been identified and many play critically important roles in digestion,
absorption and satiety signaling25. The majority of these GI neurohormones activate their
respective receptors present on vagal afferent nerve endings in a predominantly paracrine

PT
manner26–28, increasing vagal afferent firing and resulting, ultimately, in a range of visceral
effects including gastric relaxation, reduced gastric emptying, altered motility and pancreatic
secretion27–29. Ghrelin, in contrast, is released from the stomach and inhibits vagal afferent

RI
firing30 and is, to date, the only GI neurohormone that stimulates feeding directly, in addition to
attenuating the anorexigenic actions of CCK and leptin31,32.

SC
Despite being activated principally indirectly, some chemosensitive vagal afferents can
respond directly to nutrients; discrete subpopulations of gastric vagal afferents are activated33

U
while hepatic vagal afferents34 are inhibited, by elevated glucose levels. Hepatic vagal afferents
AN
innervating the portal vein are in a unique anatomical position to respond rapidly to nutrients
following intestinal absorption; their activity is also modulated by amino acids (increased or
decreased, depending on the amino acid)35 suggesting a close correlation between hepatic
M

vagal afferent activity and food ingestion.

D

Subsequent to their release, GI neurohormones enter the bloodstream from where they
TE

may also exert non-paracrine effects on vagal activity. In humans, circulating levels of platelet-
free 5-HT increase 3 fold following meal ingestion36 while CCK levels increase 5-8 fold37.
Originally thought to have a tight blood-ganglion barrier38, circulating substances39 readily
EP

access, hence potentially alter the activity of, vagal afferent somata directly. GI vagal afferent
somata display a variety of receptors for neurotransmitters/modulators40 and in virtually every
instance studied to date, the actions of GI neurohormones on vagal afferent neurons mimic
C

those at their peripheral terminals (see 32,33,41,42).

AC

Several of these GI neurohormones also act centrally to modulate the activity of

brainstem vagal neurons. CCK, GLP-1 and 5-HT, for example, also all act as
neurotransmitters/modulators within the brainstem to affect vagal afferent and efferent
responses either directly or indirectly43–46. We have demonstrated previously that CCK can
activate NTS neurons even after selective surgical section of vagal afferent rootlets, implying a
direct central action44. While the contribution of paracrine vs hormonal modulation of vagal

6
 ACCEPTED MANUSCRIPT

neurocircuits by GI neurohormones is not clear, GI neurohormones appear capable of exerting

coordinated, but temporally distinct, actions to regulate vagally dependent functions.

High fat diet and obesity compromise vagal plasticity

Studies from several laboratories have demonstrated that, in both humans and animal

PT
models, the ability of vagal afferents to respond to GI neuropeptides is compromised by obesity
or exposure to a high fat diet. The actions of CCK, for example, to increase vagal afferent
activity is reduced in obese rodents as well as humans47–49. Similarly, subpopulations of vagal

RI
afferent neurons from rats fed a high fat diet become leptin resistant at the onset of
hyperphagia50. It should also be noted though that, rather than the actions of leptin being

SC
attenuated uniformly following conditions of excess energy intake, an action of leptin to inhibit
gastric tension receptors in mice only becomes apparent after exposure to a high fat diet. Such
changes appear to act in concert, however, to promote increased food intake51. Several groups

U
have demonstrated that vagal neurocircuits exhibit a significant degree of plasticity and their
AN
‘response phenotype’, is modulated by ongoing physiological, and pathophysiological,
conditions52–54. Under fasting conditions, when circulating CCK levels are low, the density of
cannabinoid (CB1), and melanin concentrating hormone (MCH1) receptors on vagal afferent
M

neurons is increased; this ‘orexigenic phenotype’ is associated with an increase in food intake.
Conversely, following re-feeding, or an increase in circulating CCK levels, Y2 receptor
D

expression increases while CB1 receptor expression decreases; this ‘anorexigenic phenotype’
TE

is associated with a decrease in food intake52. In diet-induced obesity, however, vagal afferent
neurons appear fixed in an orexigenic phenotype, regardless of feeding status, supportive of an
increased ‘drive’ for food intake or a decreased satiety response52. Furthermore, in diet-induced
EP

obese mice, the mechanosensitivity of vagal afferents is reduced55 and one recent study
suggested that the ghrelin’s inhibitory actions on vagal afferent firing are lost56, suggestive of a
more wide-spread dysregulation of vagal afferents, not merely a loss of satiety signaling. In
C

contrast, other studies demonstrated that, rather than losing efficacy, in obese mice ghrelin is
AC

able to inhibit the activation of both gastric mucosal and tension sensitive vagal afferents, which
would be expected to increase its orexigenic actions55.

While technical differences between studies may explain some of these differences,
clearly the effects of diet and obesity on vagal afferent responsiveness is multifactorial and is
likely to be affected by vagal afferent type, sex, time of day and feeding status. In general, both
vagal afferent and efferent neurons appear less excitable in diet-induced obese rodent

7
 ACCEPTED MANUSCRIPT

models48–50,52–57; a generalized decrease in neuronal excitability would compromise the ability of

vagal afferents and efferents to respond to any signal, mechanical or chemical47,50,55,57.

A decrease in neuronal excitability is unlikely to be the sole mechanism behind loss of

vagal afferent responsiveness, however. Gene expression levels of the growth hormone
secretagogue (ghrelin) receptor shows a diurnal rhythm58 and the mechanosensitivity of gastric

PT
vagal afferents shows a striking circadian rhythm, decreasing three-fold during the dark cycle
when feeding in mice is prevalent59 implying that vagal afferent responsiveness to food

RI
ingestion is dictated by feeding cycles and the time of day. This circadian dependency is lost in
obesity, however, in concert with a loss in ability of leptin to increase mechanosensitivity,

SC
increasing daytime feeding60.

It remains to be determined whether these changes in vagal afferent properties with

U
obesity are correlative or causative, however. One recent study suggests that, in rats, the ability
of glucose to modulate serotonin signaling in GI vagal afferents is lost after only 3-7 days of
AN
exposure to a high fat diet, implying that reduced vagal sensory signaling is affected prior to
obesity. Even one day of exposure to a high fat diet increases the recruitment of classically
M

activated macrophages (M1) to the nodose ganglion of mice, suggesting that even short term
exposure can induce inflammation in the vagal afferent system61.
D

Effects of gut microbiota on vagal afferents

TE

A significant, and growing, body of literature supports the actions of gastrointestinal

luminal microorganisms to modulate gut-brain signaling via vagal afferents, the so-called
EP

microbiota-gut-brain axis (MGB axis; see reviews62–64). While gut microbiota might normally be
expected to activate vagal afferents directly only under conditions where intestinal permeability
is compromised (e.g. following inflammation or stress), luminal bacteria may activate vagal
C

afferents indirectly, subsequent to stimulation and release of neuroactive mediators from

AC

enteroendocrine cells or gut associated lymphoid tissue (GALT). In addition to their potential
role in the regulation of gut functions including motility and secretion, and activation of immune
responses, the gut microbiota have well-described roles in ‘higher’ CNS functions, including
mood, stress-related psychiatric conditions and memory63,64. Administration of Citrobacter
rodentium to mice, for example, increases anxiety-like behaviors in a vagally-dependent
manner65 while Bifidobacterium longum NC3001 normalized anxiety-like behavior following
nematode-induced GI inflammation, again in a manner involving the vagus nerve66. Clinical

8
 ACCEPTED MANUSCRIPT

studies have also suggested that ingestion of probiotics may decrease anxiety and
depression67. Large clinical trials evaluating the efficacy of antibiotic as well as probiotic
(“psychobiotic”) therapies, as well as in-depth sequencing of the microbiome, is required as a
matter of urgency to further elaborate on the role of the MGB axis in several pathophysiological
states.”

PT
Inflammation and modulation of vagal afferents

RI
Vagal afferents and neurons respond directly to cytokines and endotoxin, not only
contributing to the induction of fever and sickness behavior, but also affecting GI function.

SC
Indeed, interleukin-1 (IL-1) receptors are expressed on vagal afferents and glomus cells
adjacent to the VN68,69 while intestinal inflammation, triggered by Campylobacter jejuni
infection70 or intestinal manipulation71 activates NTS neurons. Inflammation, including intestinal

U
inflammation, and an increase in circulating levels of cytokines are well recognized sequelae of
AN
obesity72. Indeed, chronic exposure to low doses of the bacterial endotoxin, lipopolysaccharide
(LPS), mimics several obesity-associated outcomes including attenuated vagal afferent leptin
signaling, hyperphagia, and decreased CCK-induced satiation73 suggesting that inflammation
M

plays a causal role in obesity development. Vagal afferents can not only respond to cytokines
and inflammatory mediators74, but inflammation induces neuroplasticity, including the
D

upregulation of transient receptor potential (TRP) channels TRPV1 and TRPA175, upregulation
of P2X receptors and augmentation of ATP signaling76, modulation of sodium ion channel
TE

density and function53, reactive gliosis of satellite glial cells76, and increased
mechanosensitivity77 suggesting a means by which vagal afferent signaling and sensitivity may
EP

be modulated by inflammation.

Increases in circulating levels of cytokines, including tumor necrosis factor alpha (TNF-a)
decreases gastric motility and emptying associated with nausea and vomiting via actions at
C

central vagal neurocircuits. Calcium imaging studies suggest that TNF-a potentiates vagal
AC

afferent terminal responses, thus activates NTS neurons78, increases DVC microglial activation
and induces DMV apoptosis via PAR1 and PAR2 receptor activation79,80. Vagal motoneurons
are also inhibited by IL-1b, partly via local synthesis of prostaglandins81, suggesting that
inflammation-associated GI disorders may result, at least in part, from dysregulation of both
afferent and efferent VN. Finally, inflammation activates DMV neurons as part of the
“inflammatory reflex”, which will be discussed in more detail below.

9
 ACCEPTED MANUSCRIPT

The inflammatory reflex

In 2000, the concept of the cholinergic anti-inflammatory pathway (CAIP) was introduced
by Kevin Tracey’s group. In a model of sepsis, VN stimulation (VNS) increased survival by

PT
reducing TNF production in the liver, and especially the spleen82. This anti-inflammatory effect
could be reproduced in vitro using isolated human macrophage cultures; the release of TNF, IL-
1b, IL-6 and IL-18 in response to endotoxin was significantly reduced by acetylcholine and

RI
nicotine. While searching for a pharmacological target of VNS, Wang et al.83 identified the
alpha7 subtype of the nicotinic acetylcholine receptor (α7nAChR) as the main receptor by which

SC
splenic macrophages are modulated. Based on these findings, the “cholinergic anti-
inflammatory pathway” was introduced whereby the VN exerts its anti-inflammatory effect by
direct modulation of macrophages and cytokine production, via α7nAChR, mainly in the spleen.

U
By restraining the magnitude of a potentially fatal peripheral immune response, this mechanism
AN
is believed to provide an additional protective mechanism against the lethal effects of
cytokines84. In comparison with the HPA axis or the local production of anti-inflammatory
cytokines, this cholinergic control seems to have several properties favoring a central role in
M

immune homeostasis. Considering the speed of neural conductance, it is capable of providing

an instantaneous modulatory input to the inflamed region. Moreover, as the nervous system can
D

adapt its output based on information obtained from different host regions, the modulatory
TE

influence of the CAIP is not only fast, but integrated with respect to the general host well-being.
This reasoning eventually has led to the introduction of the “inflammatory reflex”84.
EP

The Cholinergic Anti-Inflammatory Pathway – controversies and unresolved issues

C

Although the anti-inflammatory effect of VNS is well accepted and demonstrated in a

AC

variety of disease models, the main problem accepting the concept as proposed initially is the
absent, or very limited, vagal innervation of the spleen85. The adrenergic innervation of the
spleen is more abundant, however, arising from prevertebral sympathetic ganglia, particularly
from the celiac ganglion20,86. Vagal efferents have been proposed to activate these adrenergic
neurons through interaction with α7nAChR86 affecting cytokine production in the spleen via
sympathetic fibers running in the splenic nerve. These fibers are indeed in close proximity to
ChAT expressing splenic CD4+ T cells, further characterized as CD44highCD62low memory T

10
 ACCEPTED MANUSCRIPT

cells87. These T cells are rather rare in the spleen of naïve mice, however85. Nevertheless, VNS
in nude mice (deficient in T cells) fails to reduce endotoxin-induced TNF production, while
adoptive transfer of memory T cells restored the anti-inflammatory potential of VNS87. Based on
these findings, the hypothesis was put forward that adrenergic, rather than cholinergic, nerve
fibers activate acetylcholine producing memory T cells, via β-adrenoceptor activation,

PT
subsequently dampening splenic macrophages and cytokine production via interaction with
α7nAChRs (Figure 1).

RI
Still, several important discrepancies and issues remain. First, using antegrade and/or
retrograde tracing, no synaptic connection can be detected between vagal efferents and

SC
adrenergic prevertebral neurons innervating the spleen88,89. Second, although splenic
denervation and reserpine-induced depletion of adrenergic nerves abolish the anti-inflammatory
effect of VNS, splenic nerve activity cannot be detected in response to vagal efferent nerve

U
stimulation89,90. Third, splenic nerve activation reduces splenic cytokine production in a
AN
α7nAChR independent manner86. This suggests that α7nAChR+ target cells may be located
outside the spleen that migrate to, and are sequestered in, the spleen, especially in conditions
of systemic inflammation. In view of the dense innervation of almost all lymphoid structures
M

(lymph nodes, Peyer’s patches, thymus), neuromodulation may primarily occur in these
structures, after which immune cells travel to the spleen. Clearly, more research is warranted to
D

unravel the exact neuroanatomy of the vagal anti-inflammatory pathway to the spleen.
TE

Another, thus far largely neglected, issue is the fact that electrical stimulation of the
entire VN activates not only efferent, but also afferent, nerve fibers leading to stimulation of the
contralateral vagus via a central pathway86,90. Indeed, activation of the central end of the cut VN
EP

seemingly has the same anti-inflammatory properties as stimulation of the intact or efferent
VN86,90. Of note, activation of the intact (hence also afferent) VN recruits additional, distinct
C

neural pathways. For example, stimulation of the intact, but not efferent, VN evokes action
potentials in the renal sympathetic nerve90 and recruits an α7nACh-independent anti-
AC

inflammatory pathway86. Furthermore, electrical stimulation of the central end of the cut VN has
a protective effect in a model of renal ischemia, even when the contralateral VN is blocked90
suggesting the recruitment of a vago-sympathetic reflex or activation of the hypothalamic-
pituitary-adrenal axis. Finally, VNS reduces cytokine production in sepsis via vagal activation of
adrenal dopamine production91. Clearly, many issues remain to be resolved with respect to the
neural pathways activated by VNS, including whether, and where exactly, the vagal nerve
endings interact with the immune system, at least with respect to the spleen (Figure 1).

11
 ACCEPTED MANUSCRIPT

The Cholinergic Anti-Inflammatory Pathway in the gut

As the spleen has been repeatedly shown to be the major source of cytokine production
in conditions of systemic inflammation (like sepsis), it is certainly a critical site for neural control

PT
of distant organ inflammation. In conditions of more subtle or local inflammation, such as in
postoperative ileus or mild colitis, however, the spleen is not itself the site of the inflammatory

RI
insult, and other anti-inflammatory pathways may be involved. Indeed, we demonstrated
recently that VNS prevents inflammation of the muscular externa evoked by intestinal
manipulation and improves postoperative ileus92, an effect that is independent of T cells and

SC
does not involve the spleen93. This inflammatory response was associated with activation of the
NTS and DMV neurons innervating the inflamed area, compatible with the existence of a hard-

U
wired inflammatory reflex in the gut, independent of the spleen88. This observation suggests that
the CAIP may comprise two levels of activation; the first involving local modulation of
AN
inflammation that is independent of the spleen, whereas vagal modulation of the splenic
immune response is recruited when the inflammatory process becomes more generalized.
M

The GI tract receives the majority of the vagal efferent nerve fibers and harbors the most
immune cells in the body. It is to be expected, therefore, that the GI tract may be an important
D

site of vagal neuroimmune modulation. It is unlikely, however, that vagal efferents interact
directly with immune cells; using an anterograde tracing technique, we confirmed that the VN
TE

synapses mainly with the myenteric and submucosal plexuses, but maintains no direct contact
with the mucosal/submucosal or myenteric/muscular network of immune cells88,93. ChAT+ fibers
EP

originating from enteric neurons are, however, present abundantly in the submucosa and lamina
propria along the axis of each individual villus. Notably, varicose fibers approach individual
immune cells closely (less than 1uM)85 while resident macrophages in the muscularis externa
C

and the myenteric plexus are in close proximity to cholinergic nerve fibers. These data indicate
AC

that vagal neuromodulation in the intestinal wall is indirect, and occurs via the enteric nervous
system. At the level of Peyer’s patches, ChAT+ fibers are absent from follicle and dome areas,
but are consistently present within the interfollicular area where high-endothelial vessels and
many lymphocytes are contained85.

Before discussing the importance of the CAIP in the GI tract, it is fundamental to

underscore that the immune cell population residing in the submucosal/mucosal compartment
largely differs from that in the muscularis externa. The latter population is less well studied and

12
 ACCEPTED MANUSCRIPT

consists mainly of resident macrophages located between the longitudinal and circular muscle
layer at the level of the myenteric plexus. These resident macrophages have a rather
tolerogenic phenotype94, play a role in diabetic-induced gastroparesis95, postoperative ileus96
and LPS-induced septic ileus97 and seem to represent the gatekeepers of the enteric nervous
system or the “little brain of the gut”. Of note, they are in close contact with cholinergic nerve

PT
fibers and express α7nAChRs88,93. As with splenocytes, the α7nAChR agonists nicotine and
choline dampen the activation of this macrophage population, indicating that these immune cells

RI
are sensitive to cholinergic modulation (see below).

The mucosal immune system is however more complex, mainly as the constant

SC
challenge by the intestinal microbiota requires a perfectly balanced equilibrium between
tolerance and defense against foreign antigens. One of the key mechanisms for discrimination
of innocent and harmful antigens is oral tolerance, a mechanism orchestrated by the mucosal

U
immune system and dependent on FoxP3+ regulatory T cells (Tregs). We showed recently that
AN
vagotomy reduced the ability to develop oral tolerance, a finding that was associated with a
reduction in Tregs in the lamina propria and mesenteric lymph nodes98. Of note, vagotomized
mice were more susceptible to developing colitis following exposure to the mucosal irritant,
M

dextran sulfate sodium (DSS), suggesting that, in addition to TGF-β, retinoic acid and TSLP99,
vagal input, or cholinergic tone, may be a new player in determining the degree of lamina
D

propria tolerance (Figure 2). This may be relevant for several intestinal, as well as extra-
intestinal, immune-mediated diseases; decreased tolerance to microbiota, for example, is
TE

proposed as a main pathogenic mechanism in inflammatory bowel disease (Crohn’s disease

and ulcerative colitis). Food allergy is another well-known example of loss of tolerance, in which
EP

the immune system reacts to food antigens leading potentially to severe anaphylactic shock and
even death100,101. In both cases, the immune system overreacts to innocent antigens leading to
severe tissue damage, morbidity and mortality.
C

The following paragraphs will discuss the current evidence supporting the relevance of
AC

the CAIP in the GI tract. For more information on the CAIP and its physiological importance, the
reader is referred to several excellent reviews102–104.

The Cholinergic Anti-Inflammatory Pathway in intestinal inflammatory disorders

Preclinical evidence

13
 ACCEPTED MANUSCRIPT

Colitis

Inflammatory bowel disease (IBD) is a debilitating and chronic inflammatory GI disease.

Based on clinical presentation, endoscopic appearance, and histology, two major subtypes of
the disease have been identified, i.e. Crohn’s disease with transmural inflammation versus
ulcerative colitis which involves mostly superficial inflammation confined to the mucosa.

PT
Preclinical models provide convincing evidence that the cholinergic innervation of the gut has a
major impact on the intestinal immune system. As indicated above, vagotomized animals fail to

RI
develop oral tolerance98 and develop more severe colitis with increased levels of NF-kB and
cytokines in DSS and hapten-induced (dinitrobenzene sulfonic acid or DNBS) colitis98,105,106.

SC
Similarly, mice with depressive-like behavior following chronic reserpine treatment, which is
associated with reduced intestinal levels of acetylcholine, developed more severe DSS and
DNBS-induced colitis107. Of interest, treatment with the anti-depressant desimipramine reversed

U
these effects in a vagus-dependent manner. In contrast, vagotomy does not affect T cell
AN
transfer-induced colitis98,108, indicating that T cells are less likely to be under direct
vagal/cholinergic control. Macrophages or dendritic cells may be more likely to be involved;
vagotomy had no effect on colitis in macrophage deficient mice105, while adoptive transfer of
M

macrophages isolated from vagotomized mice or mice treated with reserpine to macrophage-
deficient M-CSF-/- mice produced a modest, but significant, increase in severity of colitis109.
D

These data may at least partly explain how psychological factors such as depressive mood
associated with anxiety predict the onset in IBD patients109,110. Taken together, the above would
TE

suggest that the intestinal cholinergic tone, through vagal input, has a significant modulatory
effect on the gut immune system, determining the balance between tolerance and inflammation,
EP

and affecting the susceptibility to develop colitis. (Figure 2)

Data on VNS in colitis models is rather limited and restricted to rats, principally because
the electrodes for chronic VNS available need to be reduced in size to be suitable for
C

implantation in mice. A single episode of VNS significantly improves oxazolone-induced111 and

AC

DSS-induced (unpublished data) colitis in mice, an effect that is independent of the spleen. In a
rat model of TNBS colitis, chronic VNS slightly reduced disease activity index, histological
scores, MPO activity, iNOS, TNF-α and IL-6, an effect mediated by disruption of the NF-κB
pathway112,113. A more pronounced reduction in DSS and DNBS-induced colitis was noted using
nicotine, an effect resistant to vagotomy106, and following activation of brainstem vagal
neurocircuits using centrally acting drugs like the M1 muscarinic agonist McN-A-343, the M2
muscarinic antagonist methoctramine, or the acetylcholine esterase inhibitor galantamine114.The

14
 ACCEPTED MANUSCRIPT

beneficial effect of central pharmacological activation of the VN was associated with decreased
MHC class II expression and reduced cytokine production of splenic CD11c+ splenocytes, most
likely resulting in decreased priming of CD4+CD25- T cells in the spleen. How these findings
relate to the reduction in colonic inflammation, however, remains to be explored. As splenic
denervation abolished the beneficial effect of central cholinergic activation, the authors

PT
proposed the involvement of a vagal-splenic nerve circuit114. Of note, however, splenic
denervation increased colitis to a similar extent as vagotomy. Given that splenic macrophages
are mainly modulated by adrenergic input115, with increased splenic macrophage activation and

RI
TNF-α production following adrenergic denervation of the spleen, splenic denervation will
undoubtedly obscure the beneficial effect of central VN activation. It is impossible, therefore, to

SC
dissect out the extent to which central vagus activation affects splenic function via the splenic
nerve. Moreover, as pointed out earlier, no anatomic or electrophysiological evidence is

U
available to support such neurocircuitry. Direct modulation of the intestinal immune system,
especially in view of the dense cholinergic innervation of the intestine, may be an alternative
AN
explanation for the beneficial effect of central acting compounds, with entrapment of intestine- or
secondary lymphoid tissue-modulated immune cells in the spleen. Clearly, this hypothesis, and
M

the exact role of the spleen in colitis, require further study. Nevertheless, the concept of central
activation of the vagal anti-inflammatory pathway is very appealing and may be a promising new
approach to treat IBD.
D

In models of sepsis, α7nAChRs have been repeatedly shown to mediate the beneficial
TE

effect of VNS4,83. Their role in colitis, however, is somewhat controversial. We showed recently
the intact development of oral tolerance and lack of increased susceptibility for development of
EP

DSS-induced or T cell transfer colitis in α7nAChR-/- mice98, while DSS colitis was worsened by
treatment with selective α7nAChRs agonists (AR-R17779, GSK1345038A)116. Conversely,
others reported more severe DSS-induced colitis and increased IL-1b and IL-6 levels in colonic
C

tissue of α7nAChR-/- mice110 while cytokine production of splenocytes and splenic CD11c+ cells
AC

isolated from colitis mice is reduced by the α7nAChR agonist GTS-21. Such controversies are
not restricted to preclinical models since, in IBD patients, it remains to be determined why
nicotine and smoking is associated with improvement of disease activity in ulcerative colitis but
has an opposite effect in Crohn’s colitis. Differences in expression of α7nAChR, depending on
the state of maturation and the inflammatory microenvironment, may partly explain these
seemingly contradictory observations. For example, oxazolone-induced colitis was associated
with an IL-4 mediated upregulation of α7nAChR on colonic CD4 T cells which resulted in a

15
 ACCEPTED MANUSCRIPT

beneficial response to nicotine. Conversely, α7nAChR expression was down-regulated in an IL-

12 dependent manner in TNBS-induced colitis and was associated with a worsening of colitis by
nicotine117. To what extent this also applies to IBD patients remains however to be confirmed.

PT
Ischemia –reperfusion intestinal damage

Ischemia due to severe blood loss, cardiac arrest or arterial occlusion results in severe

RI
cell damage and organ injury. Tissue damage, in addition to endotoxemia resulting from
disruption of the intestinal barrier due to ischemia, is a potent trigger for the innate immune

SC
system resulting in a systemic inflammatory response. Indeed, hemorrhagic shock increases
intestinal mucosal permeability with bacterial translocation and detectable endotoxin levels as
well as systemic release of pro-inflammatory cytokines such as TNF-α and IL-6 . Of note, high-

U
fat enteral nutrition prevents these changes, an effect mediated via cholecystokinin-induced
AN
activation of vagal afferents triggering the CAIP119. In addition to its known effect on
macrophages, a recent study showed vagal-mediated expansion of enteric neural stem cells
with an increase in enteric glia and recovery of barrier function120. In agreement with these
M

studies, VNS protected against burn-induced intestinal injury and restored barrier function
through activation of enteric glia cells, independently from the spleen121. Of note, and similar to
D

colitis, administration of nicotinic agonists and central activation of the vagal CAIP by ghrelin
and melanocortins reduces the inflammatory response and restores organ function122,123.
TE
EP

Postoperative and endotoxin-induced ileus

C

Every abdominal surgical intervention leads to impaired motility of the entire GI tract
AC

lasting several days with symptoms like nausea, vomiting, intolerance to food and absence of
defecation, referred to as postoperative ileus (POI). Although some would argue that this
represents a physiological response to the surgical insult and should not be regarded as a
clinical problem, this iatrogenic condition is a major source of patient morbidity and a significant
economic burden to health care96,124. For more than a decade, a subtle microscopic
inflammation of the intestinal muscularis, triggered by activation of resident macrophages
residing between the longitudinal and circular muscle layer of the intestinal wall, has been

16
 ACCEPTED MANUSCRIPT

identified as key process in the pathophysiology of POI and endotoxin-induced ileus. Activation
of these phagocytes results in cytokine and chemokine release, followed by influx of mainly
leukocytes and monocytes starting approximately 3-4 hours after surgery. As this inflammatory
response has a major impact on neuromuscular function, treatments or interventions hampering
this process may be instrumental in reducing POI96.

PT
Several lines of preclinical evidence indicate that activation of the CAIP may be an
efficient strategy to prevent POI. Stimulation of the vagus, either electrically92, via enteral

RI
feeding125 or central application of semapimod116, all reduced the influx of immune cells into the
muscularis, dampened cytokine production, and improved GI transit. The effect of VNS is

SC
mediated by vagal activation of cholinergic myenteric neurons, resulting in reduced activation of
resident muscular macrophages. The latter express α7nAChR, explaining the lack of a
beneficial effect of VNS in α7nAChR-/- mice93. Of note, pharmacological stimulation of these

U
neurons with the 5-hydroxytryptamine 4 receptor agonists mosapride or prucalopride mimics the
AN
effect of VNS126,127. Finally, the selective α7nAChR agonist, AR-R17779, improved intestinal
transit and reduced intestinal inflammation116. Of note, and in contrast to the neurocircuitry
proposed in sepsis models, vagal modulation of intestinal resident macrophages is independent
M

of T cells and results from a direct input to the gut; selective denervation of the spleen leaves
the modulatory effect of the VN untouched, arguing against the spleen as site of
D

neuromodulation, at least in this model of subtle intestinal inflammation93.

TE

Human evidence
EP

Accepting that the VN has a major impact on the immune system, one would anticipate
increased incidence of intestinal inflammation in patients who undergo vagotomy. To date,
C

however, solid data supporting this assumption are not available. One study reports increased
ulcer disease, septicemia and mortality in patients that underwent vagotomy following traumatic
AC

injury128 although this increased incidence of inflammatory-mediated adverse outcomes may be

a consequence of an increased need for gastrectomy and vagotomy in the more severe
cases128. One possible explanation for the lack of increased intestinal inflammation may be that
cholinergic tone is restored by compensatory increase within the enteric nervous system. In
mice, the increased susceptibility to DSS colitis following vagotomy indeed normalizes after
several weeks129. To what extent similar compensatory mechanisms are activated in other
regions of the body remains to be studied.

17
 ACCEPTED MANUSCRIPT

There is however increasing indirect evidence, based on heart rate variability monitoring,
130,131
to support an immune-modulatory role of the CAIP in humans (reviewed in ). In healthy
subjects, reduced heart rate variability indices (= low vagal tone) are independently associated
with increased serum CRP and IL-6 levels and increased TNF and IL-6 production in endotoxin-
stimulated whole blood. Also, in immune-mediated diseases like rheumatoid arthritis, VN activity

PT
was reduced compared to healthy controls and associated with increased levels of serum
HMGB1, while parasympathetic tone is inversely related to inflammatory markers (IL-6 and
CRP) in patients with cardiovascular disease. Finally, increased morbidity and mortality

RI
following cardiac surgery, myocardial infarction, sepsis, RA, IBD, lupus erythematosus and
sarcoidosis has been reported to be associated with decreased VN activity. These data suggest

SC
that reduced vagal tone increases the setpoint of the immune response with a subtle rise in pro-
inflammatory cytokines and increased disease risk.

U
The final evidence that activation of the vagal anti-inflammatory pathway is, indeed, a
AN
breakthrough for the clinical management of immune-mediated inflammatory diseases will
ultimately have to come from clinical trials evaluating specific nicotinic agonists or electrical,
pharmacological or nutritional activation of the CAIP. The effect of nicotine (rectal enemas or
M

transdermal application) has been extensively evaluated in patients with ulcerative colitis albeit
with controversial results132. Side effects due to interaction with several nAChR subtypes and
D

toxicity issues most likely prevent effective dosing with nicotine. Activation of the CAIP by early
enteral nutrition improved clinical recovery in patients undergoing major rectal surgery and was
TE

associated with less anastomic leakage133. In contrast, despite being supposed to activate the
VN, gum chewing fails to improve postoperative outcome after colorectal surgery134. Finally,
EP

electrical stimulation of the VN, either in the neck, the abdominal cavity, or the ear, may be
considered as treatment for chronic inflammatory diseases such as IBD and rheumatoid arthritis
(RA), and will be discussed in more detail in the following paragraph.
C
AC

Treatment options – VNS in humans

VNS is currently routinely and safely used in patients with intractable epilepsy,
depression and migraine135. To this end, a coiled electrode is surgically positioned around the
cervical VN and connected to a pacemaker. Transcutaneous auricular VNS, contrast, stimulates
the auricular branch of the VN using a dedicated intra-auricular electrode. Finally, the cervical

18
 ACCEPTED MANUSCRIPT

VN can be stimulated transcutaneously by low voltage electrical signals delivered by a handheld

device (reviewed in136).

VNS refers, commonly, to electrical stimulation of the left cervical vagus, the right vagus
being thought to be more closely associated with cardiovascular functions. While not effective
acutely, long-term (>9-12 months) VNS has been shown to have clinically relevant outcomes, in

PT
both unipolar and bipolar depression, in patients that fail to respond to multiple antidepressant
drugs137. The mechanism of VNS action to modulate mood is not understood fully, but since the

RI
NTS (the principle termination site of vagal afferents) projects to multiple brainstem, midbrain
and forebrain nuclei, VNS has the potential to modulate several CNS-dependent functions. Both

SC
animal and human studies have suggested that VNS alters neurotransmitter levels centrally;
increased serotonin levels138, increased locus ceruleus norepinephrine signaling139, altered NTS
GABA and glutamate signaling140, and enhanced cortical inhibition141 have all been proposed to

U
be responsible for the efficacy of VNS in treating epilepsy.
AN
The anti-inflammatory effects of VNS were evaluated initially in epilepsy patients; VNS
reduced IL-6 and increased IL-10 serum levels142,143 and diminished IL-8, TNF, IL-1B and IL-6
production by isolated peripheral blood mononuclear cells144,145. Recently, a small open pilot
M

study in patients with RA provided the first evidence in humans that VNS, indeed, has the
potential to improve immune-mediated diseases145. Cervical VNS improved RA disease activity,
D

reduced TNF production and dampened cytokine production of peripheral blood. Similarly, 5 out
TE

of 7 patients with Crohn’s disease improved following cervical VNS and remained in remission
during the 6 months follow-up146. Finally, abdominal VNS during abdominal surgery reduced IL-
6 and IL-8 production of LPS-stimulated peripheral blood147. Randomized and sham-controlled
EP

trials are ongoing in Crohn’s disease (NCT02311660) and postoperative ileus (NCT02524626,
NCT02425774) hopefully further confirming the therapeutic potential of VNS.
C

The use of VNS in the treatment of obesity has also gained some initial attention148,
AC

despite evidence of only a rather modest weight loss; studies in obese minipig models have
shown that long-term bilateral VNS prevents further weight gain and decreases food
consumption149 rather than reversing obesity per se. Again, the mechanism responsible for
these effects is unclear, although activation of the olfactory bulb and its projection pathways, as
well as activation of the hippocampus and pallium (involved in assigning hedonic value to
ingestive signals) have been reported149. Shorter periods of VNS have been shown to activate

19
 ACCEPTED MANUSCRIPT

the mesolimbic dopaminergic system suggesting some of the effects on food intake and weight
gain may be related to activation of central reward pathways150.

In contrast to the modest effects of VNS to reduce or reverse obesity, vagal nerve
blockade (vBloc), designed as an alternative to standard bariatric surgery, has proven much
more efficient in inducing significant weight loss, early and more prolonged satiation and

PT
improved glycemic regulation151,152. While this appears initially to directly contradict the actions
of VNS to induce weight loss, it is perhaps not that surprising since it has been known for some

RI
time that truncal vagotomy improves obesity, including exogenous (hypothalamic) obesity in
rodents83 and humans153,154. Vbloc uses a cuff electrode that encircles the VN and employs

SC
kilohertz frequency alternating current, with zero net charge delivery, to produce a very
localized, true nerve conduction (rather than a neurotransmitter) block, that is rapidly reversible
and does not induce any apparent nerve degeneration or damage (reviewed in155). Biophysical

U
modeling studies suggest that a depolarization induced inactivation of sodium channels is
AN
responsible for the nerve block in mammalian nerves155 although the contribution of afferent
versus efferent VN block still remains to be elucidated.
M

Conclusion
D

While a few decades ago, cutting the vagus nerve represented a well accepted
TE

treatment for peptic ulcer disease, it is now clear that this nerve is extremely precious not only
for the homeostasis of a variety of organ systems, but also for the regulation of appetite, mood
and inflammation. The therapeutic potential of stimulating or blocking the VN, either electrically
EP

or pharmacologically, is being explored gradually, and the exact pathways and mechanisms of
action are becoming understood. Non-invasive devices to stimulate the VN have been
C

developed, although the optimal stimulation parameters and the type of nerve fibers to be
stimulated remain to be determined. Clinical studies are ongoing and will hopefully soon confirm
AC

that the VN should be handled with great care rather than being cut.

20
 ACCEPTED MANUSCRIPT

Legends to figures

Figure 1:

Schematic representation of the cholinergic anti-inflammatory pathway.

PT
VNS of the intact vagus nerve stimulates both afferent and efferent fibers. Electrical stimulation
of afferent nerve fibers activates neurons in the NTS leading to activation of not only both ipsi-
and contralateral efferent vagus nerves, but also of an adrenergic pathway resulting in release

RI
of norepinephrine (NE) in the spleen and the production of dopamine (DA) in the adrenal gland.
In the spleen, NE reduces TNF production by splenic macrophages both directly, via actions on
β2 adrenoceptor activation, and indirectly, via activation of CHAT+ T cells releasing ACh.

SC
Activation of presynaptic α7nAChR on adrenergic nerve fibers156 by choline or other α7nAChR
agonists may increase NE release contributing to their anti-inflammatory properties. Stimulation
of the efferent vagus nerve dampens α7nAChR+ resident muscular macrophages in the

U
gastrointestinal tract via activation of cholinergic enteric neurons. The immune cell(s) modulated
in the lamia propria, however, still need to be identified. The extent to which efferent vagus
AN
fibers exert an anti-inflammatory effect in the spleen by synapsing with adrenergic
postganglionic (α7nAChR+) neurons in the celiac ganglion is a matter of debate since no
anatomical or electrophysiological evidence supporting this connection is available. As the
M

vagus nerve innervates the thymus, Peyers’ patches and other myeloid organs, one may
hypothesize that cholinergic modulation of immune cells (α7nAChR+ macrophages, CHAT+, T
cells) occurs in these organs. Under conditions of systemic inflammation, these cells
D

subsequently migrate, or get trapped in the spleen, via the circulation.

TE

Figure 2:

The cholinergic tone determines immune homeostasis either shifting the balance towards
EP

tolerance (normal to enhanced tone) or inflammation (decreased tone).

C
AC

21
 ACCEPTED MANUSCRIPT

Reference list

1. Browning, K. N. & Travagli, R. A. Central nervous system control of gastrointestinal

motility and secretion and modulation of gastrointestinal functions. Compr. Physiol 4,
1339–1368 (2014).

PT
2. Altschuler, S. M., Escardo, J., Lynn, R. B. & Miselis, R. R. The Central Organization of
the vagus nerve innervating the colon of the rat. Gastroenterol 104, 502–509 (1993).

RI
3. Berthoud, H.-R., Carlson, N. R. & Powley, T. L. Topography of efferent vagal innervation
of the rat gastrointestinal tract. Am. J. Physiol 260, R200–R207 (1991).

SC
4. Beyak, M. & Grundy, D. in Advances in Vagal Afferent Neurobiology. (ed. Undem BJ and
Weinreich D) 315–350 (CRC Press, 2005).

U
5. Brookes, S. J., Spencer, N. J., Costa, M. & Zagorodnyuk, V. P. Extrinsic primary afferent
AN
signalling in the gut. Nat. Rev. Gastroenterol. Hepatol 10, 286–296 (2013).

6. Berthoud, H.-R. & Neuhuber, W. L. Functional and chemical anatomy of the afferent
vagal system. Auton. Neurosci 85, 1–17 (2000).
M

7. Andresen, M. C. & Yang, M. Non-NMDA receptors mediate sensory afferent synaptic

D

transmission in medial nucleus tractus solitarius. Am. J. Physiol 259, H1307–H1311

(1990).
TE

8. Rinaman, L., Card, J. P., Schwaber, J. S. & Miselis, R. R. Ultrastructural Demonstration

of a Gastric Monsynaptic Vagal Cirucit in the Nucleus of the Solitary Tract in Rat. J.
EP

Neurosci. 9, 1985–1996 (1989).

9. Leslie, R. A. & Gwyn, D. G. Neuronal connections of the area postrema. Fed. Proc 43,
C

2941–2943 (1984).
AC

10. Cottrell, G. T. & Ferguson, A. V. Sensory circumventricular organs: central roles in

integrated autonomic regulation. Regul. Pept 117, 11–23 (2004).

11. Orts-Del’immagine, A. et al. Properties of subependymal cerebrospinal fluid contacting

neurones in the dorsal vagal complex of the mouse brainstem. J. Physiol 590, 3719–3741
(2012).

12. Altschuler, S. M., Bao, X., Bieger, D., Hopkins, D. A. & Miselis, R. R. Viscerotopic

22
 ACCEPTED MANUSCRIPT

Representation of the Upper Alimentary Tract in the Rat: Sensory Ganglia and Nuclei of
the Solitary and Spinal Trigeminal Tracts. J. Comp. Neurol. 283, 248–268 (1989).

13. Sivarao, D. V, Krowicki, Z. K. & Hornby, P. J. Role of GABAA receptors in rat hindbrain
nuclei controlling gastric motor function. Neurogastroenterol. Motil. 10, 305–313 (1998).

PT
14. Travagli, R. A., Gillis, R. A., Rossiter, C. D. & Vicini, S. Glutamate and GABA-mediated
synaptic currents in neurons of the rat dorsal motor nucleus of the vagus. Am. J. Physiol
260, G531–G536 (1991).

RI
15. Davis, S. F., Derbenev, A. V, Williams, K. W., Glatzer, N. R. & Smith, B. N. Excitatory and

SC
inhibitory local circuit input to the rat dorsal motor nucleus of the vagus originating from
the nucleus tractus solitarius. Brain Res 1017, 208–217 (2004).

U
16. Shapiro, R. E. & Miselis, R. R. The Central Organization of the Vagus Nerve Innervating
the Stomach of the Rat. J. Comp. Neurol. 238, 473–488 (1985).
AN
17. Fox, E. A. & Powley, T. L. Longitudinal columnar organization within the dorsal motor
nucleus represents separate branches of the abdominal vagus. Brain Res 341, 269–282
M

(1985).

18. Huang, X. F., Tork, I. & Paxinos, G. Dorsal motor nucleus of the vagus nerve: a cyto- and
D

chemoarchitectonic study in the human. J Comp Neurol 330, 158–182 (1993).

TE

19. N.R., B. & Standring, S. Gray’s Anatomy. The anatomical basis of clinical practice.
(Elsevier, 2008).
EP

20. Berthoud, H. R. & Powley, T. L. Characterization of vagal innervation to the rat celiac,
suprarenal and mesenteric ganglia. J. Auton. Nerv. Syst. 42, 153–69 (1993).
C

21. Cano, G., Sved, A. F., Rinaman, L., Rabin, B. S. & Card, J. P. Characterization of the
AC

central nervous system innervation of the rat spleen using viral transneuronal tracing. J.
Comp. Neurol. 439, 1–18 (2001).

22. Berthoud, H. R. The vagus nerve, food intake and obesity. Regul. Pept 149, 15–25
(2008).

23. Saper, C. B., Chou, T. C. & Elmquist, J. K. The need to feed: homeostatic and hedonic
control of eating. Neuron 36, 199–211 (2002).

23
 ACCEPTED MANUSCRIPT

24. Powley, T. L., Spaulding, R. A. & Haglof, S. A. Vagal afferent innervation of the proximal
gastrointestinal tract mucosa: chemoreceptor and mechanoreceptor architecture. J Comp
Neurol 519, 644–660 (2011).

25. Steinert, R. E. & Beglinger, C. Nutrient sensing in the gut: interactions between
chemosensory cells, visceral afferents and the secretion of satiation peptides. Physiol

PT
Behav 105, 62–70 (2011).

26. Raybould, H. E. Mechanisms of CCK signaling from gut to brain. Curr. Opin. Pharmacol

RI
7, 570–574 (2007).

SC
27. Owyang, C. Physiological mechanisms of cholecystokinin action on pancreatic secretion.
Am. J. Physiol 271, G1–G7 (1996).

U
28. Takahashi, T. & Owyang, C. Mechanism of cholecystokinin-induced relaxation of the rat
stomach. J. Auton. Nerv. Syst 75, 123–130 (1999).
AN
29. Zhu, J. X., Wu, X. Y., Owyang, C. & Li, Y. Intestinal serotonin acts as a paracrine
substance to mediate vagal signal transmission evoked by luminal factors in the rat. J.
M

Physiol. 530, 431–442 (2001).

30. Date, Y. Ghrelin and the vagus nerve. Methods Enzym. 514, 261–269 (2012).
D

31. Date, Y. et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and
TE

growth hormone secretion in rats. Gastroenterology 123, 1120–1128 (2002).

32. Grabauskas, G. et al. KATP channels in the nodose ganglia mediate the orexigenic
EP

actions of ghrelin. J. Physiol 593, 3973–3989 (2015).

33. Grabauskas, G., Song, I., Zhou, S. Y. & Owyang, C. Electrophysiological identifications of
C

glucose-sensing neurons in the rat nodose ganglia. J. Physiol 588, 617–632 (2010).
AC

34. Niijima, A. Glucose-sensitive afferent nerve fibres in the hepatic branch of the vagus
nerve in the guinea-pig. J Physiol 332, 315–323 (1982).

35. Niijima, A. & Meguid, M. M. An electrophysiological study on amino acid sensors in the
hepato-portal system in the rat. Obes. Res 3 Suppl 5, 741S–745S (1995).

36. Houghton, L. A., Atkinson, W., Whitaker, R. P., Whorwell, P. J. & Rimmer, M. J.
Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal

24
 ACCEPTED MANUSCRIPT

ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel

syndrome. Gut 52, 663–670 (2003).

37. Liddle, R. A., Goldfine, I. D., Rosen, M. S., Taplitz, R. A. & Williams, J. A. Cholecystokinin
bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to
gallbladder contraction. J. Clin. Invest 75, 1144–1152 (1985).

PT
38. ten Tusscher, M. P., Klooster, J. & Vrensen, G. F. Satellite cells as blood-ganglion cell
barrier in autonomic ganglia. Brain Res 490, 95–102 (1989).

RI
39. Lacolley, P. et al. Occipital artery injections of 5-HT may directly activate the cell bodies

SC
of vagal and glossopharyngeal afferent cell bodies in the rat. Neuroscience 143, 289–308
(2006).

U
40. Zhuo, H., Ichikawa, H. & Helke, C. J. Neurochemistry of the nodose ganglion. Prog.
Neurobiol 52, 79–107 (1997).
AN
41. Gaisano, G. G., Park, S. J., Daly, D. M. & Beyak, M. J. Glucagon-like peptide-1 inhibits
voltage-gated potassium currents in mouse nodose ganglion neurons.
M

Neurogastroenterol. Motil 22, 470–9, e111 (2010).

42. Troy, A. E. & Browning, K. N. High fat diet decreases glucose-dependent modulation of 5-
D

HT responses in gastrointestinal vagal afferent neurons. J Physiol 594, 99–114 (2016).

TE

43. Browning, K. N. & Travagli, R. A. Characterisation of the in vitro effects of 5-

Hydroxytryptamine (5-HT) on identified neurones of the rat dorsal motor nucleus of the
EP

vagus (DMV). Br. J. Pharmacol 128, 1307–1315 (1999).

44. Baptista, V., Browning, K. N. & Travagli, R. a. Effects of cholecystokinin-8s in the nucleus
C

tractus solitarius of vagally deafferented rats. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 292, R1092–100 (2007).
AC

45. Browning, K. N., Wan, S., Baptista, V. & Travagli, R. A. Vanilloid, purinergic, and CCK
receptors activate glutamate release on single neurons of the nucleus tractus solitarius
centralis. Am. J. Physiol Regul. Integr. Comp Physiol 301, R394–R401 (2011).

46. Viard, E., Zheng, Z., Wan, S. & Travagli, R. A. Vagally mediated, nonparacrine effects of
cholecystokinin-8s on rat pancreatic exocrine secretion. Am. J Physiol Gastrointest. Liver
Physiol 293, G493–G500 (2007).

25
 ACCEPTED MANUSCRIPT

47. Covasa, M., Grahn, J. & Ritter, R. C. High fat maintenance diet attenuates hindbrain
neuronal response to CCK. Regul. Pept 86, 83–88 (2000).

48. Daly, D. M., Park, S. J., Valinsky, W. C. & Beyak, M. J. Impaired intestinal afferent nerve
satiety signalling and vagal afferent excitability in diet induced obesity in the mouse. J.
Physiol 589, 2857–2870 (2011).

PT
49. Little, T. J., Horowitz, M. & Feinle-Bisset, C. Modulation by high-fat diets of

RI
gastrointestinal function and hormones associated with the regulation of energy intake:
implications for the pathophysiology of obesity. Am. J Clin. Nutr 86, 531–541 (2007).

SC
50. de, L. G., Barbier, de la S., Espero, E., Lee, J. & Raybould, H. E. Diet-induced obesity
leads to the development of leptin resistance in vagal afferent neurons. Am. J. Physiol
Endocrinol. Metab 301, E187–E195 (2011).

51.
U
Kentish, S. J. et al. Gastric vagal afferent modulation by leptin is influenced by food intake
AN
status. J. Physiol. 591, 1921–34 (2013).

52. Dockray, G. J. Gastrointestinal hormones and the dialogue between gut and brain. J.
M

Physiol 592, 2927–2941 (2014).

53. Bielefeldt, K., Ozaki, N. & Gebhart, G. F. Experimental ulcers alter voltage-sensitive
D

sodium currents in rat gastric sensory neurons. Gastroenterology 122, 394–405 (2002).
TE

54. Kang, Y. M., Bielefeldt, K. & Gebhart, G. F. Sensitization of mechanosensitive gastric

vagal afferent fibers in the rat by thermal and chemical stimuli and gastric ulcers. J
EP

Neurophysiol 91, 1981–1989 (2004).

55. Kentish, S. et al. Diet-induced adaptation of vagal afferent function. J Physiol 590, 209–
C

221 (2012).
AC

56. Naznin, F. et al. Diet-induced obesity causes peripheral and central ghrelin resistance by
promoting inflammation. J. Endocrinol 226, 81–92 (2015).

57. Browning, K. N., Fortna, S. R. & Hajnal, A. Roux-en-Y gastric bypass reverses the effects
of diet-induced obesity to inhibit the responsiveness of central vagal motoneurones. J
Physiol 591, 2357–2372 (2013).

58. Sato, M., Nakahara, K., Miyazato, M., Kangawa, K. & Murakami, N. Regulation of GH

26
 ACCEPTED MANUSCRIPT

secretagogue receptor gene expression in the rat nodose ganglion4591. J. Endocrinol

194, 41–46 (2007).

59. Kentish, S. J., Frisby, C. L., Kennaway, D. J., Wittert, G. a & Page, A. J. Circadian
variation in gastric vagal afferent mechanosensitivity. J. Neurosci. 33, 19238–42 (2013).

PT
60. Kentish, S. J., Vincent, A. D., Kennaway, D. J., Wittert, G. A. & Page, A. J. High-Fat Diet-
Induced Obesity Ablates Gastric Vagal Afferent Circadian Rhythms. J. Neurosci 36,

RI
3199–3207 (2016).

61. Waise, T. M. et al. One-day high-fat diet induces inflammation in the nodose ganglion and

SC
hypothalamus of mice4592. Biochem. Biophys. Res. Commun 464, 1157–1162 (2015).

62. Bravo, J. A. et al. Communication between gastrointestinal bacteria and the nervous

U
system. Curr. Opin. Pharmacol. 12, 667–72 (2012).
AN
63. Bercik, P., Collins, S. M. & Verdu, E. F. Microbes and the gut-brain axis.
Neurogastroenterol. Motil. 24, 405–13 (2012).
M

64. Borre, Y. E., Moloney, R. D., Clarke, G., Dinan, T. G. & Cryan, J. F. The impact of
microbiota on brain and behavior: mechanisms & therapeutic potential. Adv. Exp.
Med. Biol. 817, 373–403 (2014).
D

65. Bravo, J. A. et al. Ingestion of Lactobacillus strain regulates emotional behavior and
TE

central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci.
U. S. A. 108, 16050–5 (2011).
EP

66. Bercik, P. et al. The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal
pathways for gut-brain communication. Neurogastroenterol. Motil. 23, 1132–9 (2011).
C

67. Dinan, T. G. & Cryan, J. F. Melancholic microbes: a link between gut microbiota and
AC

depression? Neurogastroenterol. Motil. 25, 713–719 (2013).

68. Hansen, M. K., O’Connor, K. a, Goehler, L. E., Watkins, L. R. & Maier, S. F. The
contribution of the vagus nerve in interleukin-1beta-induced fever is dependent on dose.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R929–34 (2001).

69. Marquette, C. et al. IL-1beta, TNFalpha and IL-6 induction in the rat brain after partial-
body irradiation: role of vagal afferents. Int. J. Radiat. Biol. 79, 777–85 (2003).

27
 ACCEPTED MANUSCRIPT

70. Goehler, L. E. et al. Activation in vagal afferents and central autonomic pathways: Early
responses to intestinal infection with Campylobacter jejuni. Brain. Behav. Immun. 19,
334–344 (2005).

71. Cailotto, C. et al. Neuroanatomical evidence demonstrating the existence of the vagal
anti-inflammatory reflex in the intestine. Neurogastroenterol. Motil. 24, (2012).

PT
72. Karagiannides, I. & Pothoulakis, C. Obesity, innate immunity and gut inflammation. Curr.
Opin. Gastroenterol 23, 661–666 (2007).

RI
73. de La Serre, C. B., de, L. G. & Raybould, H. E. Chronic exposure to low dose bacterial

SC
lipopolysaccharide inhibits leptin signaling in vagal afferent neurons. Physiol Behav 139,
188–194 (2015).

U
74. Goehler, L. E. et al. Vagal immune-to-brain communication: a visceral chemosensory
pathway. Auton. Neurosci 85, 49–59 (2000).
AN
75. Schwartz, E. S. et al. Synergistic role of TRPV1 and TRPA1 in pancreatic pain and
inflammation4599. Gastroenterology 140, 1283–1291 (2011).
M

76. Hanani, M. Role of satellite glial cells in gastrointestinal pain. Front Cell Neurosci 9, 412
(2015).
D

77. Liu, C. Y., Mueller, M. H., Grundy, D. & Kreis, M. E. Vagal modulation of intestinal
TE

afferent sensitivity to systemic LPS in the rat. Am. J Physiol Gastrointest. Liver Physiol
292, G1213–G1220 (2007).
EP

78. Rogers, R. C., Van Meter, M. J. & Hermann, G. E. Tumor necrosis factor potentiates
central vagal afferent signaling by modulating ryanodine channels. J Neurosci 26, 12642–
C

12646 (2006).
AC

79. Wang, H. et al. Functional protease-activated receptors in the dorsal motor nucleus of the
vagus3544. Neurogastroenterol. Motil (2009). at
<http://www.ncbi.nlm.nih.gov/pubmed/19719510>

80. Fritze, D., Zhang, W., Li, J. Y., Chai, B. & Mulholland, M. W. TNFalpha causes thrombin-
dependent vagal neuron apoptosis in inflammatory bowel disease4601. J. Gastrointest.
Surg 18, 1632–1641 (2014).

28
 ACCEPTED MANUSCRIPT

81. Mo, Z. L., Katafuchi, T. & Hori, T. Effects of IL-1 beta on neuronal activities in the dorsal
motor nucleus of the vagus in rat brain slices4602. Brain Res. Bull 41, 249–255 (1996).

82. Borovikova, L. V et al. Vagus nerve stimulation attenuates the systemic inflammatory
response to endotoxin. Nature 405, 458–62 (2000).

PT
83. Wang, H. et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of
inflammation. Nature 421, 384–8 (2003).

RI
84. Tracey, K. J. The inflammatory reflex. Nature 420, 853–9

85. Gautron, L. et al. Neuronal and nonneuronal cholinergic structures in the mouse

SC
gastrointestinal tract and spleen. J. Comp. Neurol. 521, 3741–67 (2013).

86. Vida, G., Peña, G., Deitch, E. A. & Ulloa, L. α7-cholinergic receptor mediates vagal

U
induction of splenic norepinephrine. J. Immunol. 186, 4340–6 (2011).
AN
87. Rosas-Ballina, M. et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus
nerve circuit. Science 334, 98–101 (2011).
M

88. Cailotto, C. et al. Neuro-anatomical evidence indicating indirect modulation of

macrophages by vagal efferents in the intestine but not in the spleen. PLoS One 9,
D

e87785 (2014).
TE

89. Bratton, B. O. et al. Neural regulation of inflammation: no neural connection from the
vagus to splenic sympathetic neurons. Exp. Physiol. 97, 1180–5 (2012).
EP

90. Inoue, T. et al. Vagus nerve stimulation mediates protection from kidney ischemia-
reperfusion injury through α7nAChR+ splenocytes. J. Clin. Invest. 126, 1939–52 (2016).
C

91. Torres-Rosas, R. et al. Dopamine mediates vagal modulation of the immune system by
electroacupuncture. Nat. Med. 20, 291–5 (2014).
AC

92. de Jonge, W. J. et al. Stimulation of the vagus nerve attenuates macrophage activation
by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 6, 844–51 (2005).

93. Matteoli, G. et al. A distinct vagal anti-inflammatory pathway modulates intestinal

muscularis resident macrophages independent of the spleen. Gut 1–11 (2013).
doi:10.1136/gutjnl-2013-304676

29
 ACCEPTED MANUSCRIPT

94. Gabanyi, I. et al. Neuro-immune Interactions Drive Tissue Programming in Intestinal

Macrophages. Cell 164, 378–391 (2016).

95. Choi, K. M. et al. CD206-Positive M2 Macrophages That Express Heme Oxygenase-1

Protect Against Diabetic Gastroparesis in Mice. Gastroenterology 138, (2010).

PT
96. Boeckxstaens, G. E. & de Jonge, W. J. Neuroimmune mechanisms in postoperative ileus.
Gut 58, 1300–11 (2009).

RI
97. de Winter, B. Y. et al. Role of oxidative stress in the pathogenesis of septic ileus in mice.
Neurogastroenterol. Motil. 17, 251–61 (2005).

SC
98. Di Giovangiulio, M. et al. Vagotomy affects the development of oral tolerance and
increases susceptibility to develop colitis independently of the alpha-7 nicotinic receptor.

U
Mol. Med. 22, (2016). AN
99. Rescigno, M. Intestinal Dendritic Cells. Adv. Immunol. 107, 109–138 (2010).

100. Bischoff, S. C. Food allergy and eosinophilic gastroenteritis and colitis. Curr. Opin. Allergy
M

Clin. Immunol. 10, 238–45 (2010).

101. Bischoff, S. C. Food allergies. Curr. Treat. Options Gastroenterol. 10, 34–43 (2007).
D

102. Pavlov, V. A. & Tracey, K. J. Neural circuitry and immunity. Immunol. Res. 63, 38–57
TE

(2015).

103. Olofsson, P. S., Rosas-Ballina, M., Levine, Y. A. & Tracey, K. J. Rethinking inflammation:
EP

neural circuits in the regulation of immunity. Immunol. Rev. 248, 188–204 (2012).

104. Andersson, U. & Tracey, K. J. Neural reflexes in inflammation and immunity. J. Exp. Med.
C

209, 1057–68 (2012).

AC

105. Ghia, J. E., Blennerhassett, P., Kumar-Ondiveeran, H., Verdu, E. F. & Collins, S. M. The
Vagus Nerve: A Tonic Inhibitory Influence Associated With Inflammatory Bowel Disease
in a Murine Model. Gastroenterology 131, 1122–1130 (2006).

106. O’Mahony, C., van der Kleij, H., Bienenstock, J., Shanahan, F. & O’Mahony, L. Loss of
vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 297, R1118–26 (2009).

30
 ACCEPTED MANUSCRIPT

107. Ghia, J.-E., Blennerhassett, P. & Collins, S. M. Impaired parasympathetic function

increases susceptibility to inflammatory bowel disease in a mouse model of depression.
J. Clin. Invest. 118, 2209–18 (2008).

108. van der Kleij, H., O’Mahony, C., Shanahan, F., O’Mahony, L. & Bienenstock, J. Protective
effects of Lactobacillus rhamnosus [corrected] and Bifidobacterium infantis in murine

PT
models for colitis do not involve the vagus nerve. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 295, R1131–7 (2008).

RI
109. Ghia, J.-E., Park, A. J., Blennerhassett, P., Khan, W. I. & Collins, S. M. Adoptive transfer
of macrophage from mice with depression-like behavior enhances susceptibility to colitis.

SC
Inflamm. Bowel Dis. 17, 1474–89 (2011).

110. Ghia, J.-E. et al. Reactivation of inflammatory bowel disease in a mouse model of

U
depression. Gastroenterology 136, 2280–2288.e1–4 (2009).
AN
111. Meroni, E. et al. Su1564 Improvement of Oxazolone-Induced Colitis by Vagus Nerve
Stimulation. Gastroenterology 150, S527 (2016).
M

112. Meregnani, J. et al. Anti-inflammatory effect of vagus nerve stimulation in a rat model of
inflammatory bowel disease. Auton. Neurosci. 160, 82–89 (2011).
D

113. Sun, P. et al. Involvement of MAPK/NF-κB signaling in the activation of the cholinergic
TE

anti-inflammatory pathway in experimental colitis by chronic vagus nerve stimulation.

PLoS One 8, e69424 (2013).
EP

114. Ji, H. et al. Central cholinergic activation of a vagus nerve-to-spleen circuit alleviates
experimental colitis. Mucosal Immunol. 7, 335–47 (2014).
C

115. Nance, D. M. & Sanders, V. M. Autonomic innervation and regulation of the immune
system (1987-2007). Brain, Behavior, and Immunity 21, 736–745 (2007).
AC

116. The, F. et al. Central activation of the cholinergic anti-inflammatory pathway reduces
surgical inflammation in experimental post-operative ileus. Br. J. Pharmacol. 163, 1007–
16 (2011).

117. Galitovskiy, V. et al. Cytokine-induced alterations of α7 nicotinic receptor in colonic CD4

T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus
Th2-mediated colitis. J. Immunol. 187, 2677–87 (2011).

31
 ACCEPTED MANUSCRIPT

118. Luyer, M. D. et al. Strain-specific effects of probiotics on gut barrier integrity following
hemorrhagic shock. Infect. Immun. 73, 3686–92 (2005).

119. Luyer, M. D. et al. Nutritional stimulation of cholecystokinin receptors inhibits

inflammation via the vagus nerve. J. Exp. Med. 202, 1023–9 (2005).

PT
120. Langness, S., Coimbra, R., Eliceiri, B. P. & Costantini, T. W. Vagus nerve mediates the
neural stem cell response to intestinal injury. J. Am. Coll. Surg. 221, 871–879 (2015).

RI
121. Costantini, T. W. et al. Vagal nerve stimulation protects against burn-induced intestinal
injury through activation of enteric glia cells. Am. J. Physiol. Gastrointest. Liver Physiol.

SC
299, G1308–18 (2010).

122. Wu, R. et al. Orexigenic hormone ghrelin attenuates local and remote organ injury after

U
intestinal ischemia-reperfusion. PLoS One 3, e2026 (2008).
AN
123. Giuliani, D. et al. Melanocortins and the cholinergic anti-inflammatory pathway. Adv. Exp.
Med. Biol. 681, 71–87 (2010).
M

124. Bauer, A. J. & Boeckxstaens, G. E. Mechanisms of postoperative ileus.

Neurogastroenterol. Motil. 16 Suppl 2, 54–60 (2004).
D

125. Lubbers, T. et al. Lipid-rich enteral nutrition reduces postoperative ileus in rats via
activation of cholecystokinin-receptors. Ann. Surg. 249, 481–7 (2009).
TE

126. Tsuchida, Y. et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-
inflammatory actions via α7nACh receptors on muscularis macrophages associated with
EP

postoperative ileus. Gut 60, 638–47 (2011).

127. Gomez-Pinilla, P. J. et al. 416 Prucalopride Activates the Intestinal Cholinergic Anti-
C

Inflammatory Pathway and Prevents Postoperative Ileus. Gastroenterology 146, S–89

AC

(2014).

128. Peterson, C. Y., Krzyzaniak, M., Coimbra, R. & Chang, D. C. Vagus nerve and postinjury
inflammatory response. Arch. Surg. 147, 76–80 (2012).

129. Ghia, J.-E., Blennerhassett, P. & Collins, S. M. Vagus nerve integrity and experimental
colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G560–7 (2007).

130. Huston, J. M. & Tracey, K. J. The pulse of inflammation: heart rate variability, the

32
 ACCEPTED MANUSCRIPT

cholinergic anti-inflammatory pathway and implications for therapy. J. Intern. Med. 269,
45–53 (2011).

131. Bonaz, B., Sinniger, V. & Pellissier, S. Vagal tone: effects on sensitivity, motility, and
inflammation. Neurogastroenterol. Motil. 28, 455–62 (2016).

PT
132. Nikfar, S., Ehteshami-Ashar, S., Rahimi, R. & Abdollahi, M. Systematic Review and Meta-
Analysis of the Efficacy and Tolerability of Nicotine Preparations in Active Ulcerative
Colitis. Clinical Therapeutics 32, 2304–2315 (2010).

RI
133. Boelens, P. G. et al. Reduction of postoperative ileus by early enteral nutrition in patients

SC
undergoing major rectal surgery: prospective, randomized, controlled trial. Ann. Surg.
259, 649–55 (2014).

U
134. Atkinson, C. et al. Randomized clinical trial of postoperative chewing gum versus
standard care after colorectal resection. Br. J. Surg. 103, 962–70 (2016).
AN
135. Beekwilder, J. P. & Beems, T. Overview of the clinical applications of vagus nerve
stimulation. J. Clin. Neurophysiol. 27, 130–8 (2010).
M

136. Yuan, H. & Silberstein, S. D. Vagus Nerve and Vagus Nerve Stimulation, a
Comprehensive Review: Part II. Headache 56, 259–66 (2016).
D

137. Kosel, M. & Schlaepfer, T. E. Mechanisms and state of the art of vagus nerve
TE

stimulation4604. J. ECT 18, 189–192 (2002).

138. Ben-Menachem, E. et al. Effects of vagus nerve stimulation on amino acids and other
EP

metabolites in the CSF of patients with partial seizures4605. Epilepsy Res 20, 221–227
(1995).
C

139. Krahl, S. E., Clark, K. B., Smith, D. C. & Browning, R. A. Locus coeruleus lesions
AC

suppress the seizure-attenuating effects of vagus nerve stimulation4608. Epilepsia 39,

709–714 (1998).

140. Walker, B. R., Easton, A. & Gale, K. Regulation of limbic motor seizures by GABA and
glutamate transmission in nucleus tractus solitarius4607. Epilepsia 40, 1051–1057
(1999).

141. Marrosu, F. et al. Correlation between GABA(A) receptor density and vagus nerve

33
 ACCEPTED MANUSCRIPT

stimulation in individuals with drug-resistant partial epilepsy4606. Epilepsy Res 55, 59–70
(2003).

142. Aalbers, M. W. et al. The effects of vagus nerve stimulation on pro- and anti-inflammatory
cytokines in children with refractory epilepsy: an exploratory study.
Neuroimmunomodulation 19, 352–8 (2012).

PT
143. Majoie, H. J. M. et al. Vagus nerve stimulation in refractory epilepsy: effects on pro- and
anti-inflammatory cytokines in peripheral blood. Neuroimmunomodulation 18, 52–6

RI
(2011).

SC
144. De Herdt, V. et al. Effects of vagus nerve stimulation on pro- and anti-inflammatory
cytokine induction in patients with refractory epilepsy. J. Neuroimmunol. 214, 104–108
(2009).

U
145. Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates
AN
disease severity in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 113, 8284–9
(2016).
M

146. Bonaz, B. et al. Chronic vagus nerve stimulation in Crohn’s disease: a 6-month follow-up
pilot study. Neurogastroenterol. Motil. 28, 948–53 (2016).
D

147. Stakenborg, N. et al. Su1563 Electrical Stimulation of the Abdominal Vagus Nerve Is as
TE

Effective as Cervical Nerve Stimulation in Reducing Postoperative Ileus.

Gastroenterology 150, S527 (2016).
EP

148. Guiraud, D. et al. Vagus nerve stimulation: state of the art of stimulation and recording
strategies to address autonomic function neuromodulation4611. J. Neural Eng 13, 41002
(2016).
C

149. Val-Laillet, D., Biraben, A., Randuineau, G. & Malbert, C. H. Chronic vagus nerve
AC

stimulation decreased weight gain, food consumption and sweet craving in adult obese
minipigs4609. Appetite 55, 245–252 (2010).

150. Malbert, C. H. [The brain-gut axis: insights from the obese pig model]4610. Bull. Acad.
Natl. Med 197, 1683–1694 (2013).

151. Sarr, M. G. et al. The EMPOWER study: randomized, prospective, double-blind,

multicenter trial of vagal blockade to induce weight loss in morbid obesity4617. Obes.

34
 ACCEPTED MANUSCRIPT

Surg 22, 1771–1782 (2012).

152. Morton, J. M. et al. Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-
Related Comorbid Condition: the ReCharge Study4618. Obes. Surg 26, 983–989 (2016).

153. Kral, J. G. Vagotomy for treatment of severe obesity4612. Lancet 1, 307–308 (1978).

PT
154. Kral, J. G. & Gortz, L. Truncal vagotomy in morbid obesity4613. Int. J. Obes 5, 431–435
(1981).

RI
155. Kilgore, K. L. & Bhadra, N. Reversible nerve conduction block using kilohertz frequency
alternating current4619. Neuromodulation 17, 242–254 (2014).

SC
156. Downs, A. M., Bond, C. E. & Hoover, D. B. Localization of alpha7 nicotinic acetylcholine
receptor mRNA and protein within the cholinergic anti-inflammatory pathway.

U
Neuroscience 266, 178–185 (2014).
AN
M
D
TE
C EP
AC

35
 ACCEPTED MANUSCRIPT
Table 1: CNS nuclei with direct connections with vagal brainstem nuclei involved in the regulation of GI functions1

Location Neuroanatomical connections GI functions

with brainstem vagal nuclei
Hindbrain
Relay nociceptive information; spinal
Spinal afferent inputs terminate
Spinal cord GI afferents terminate within within the NTS (spinosolitary afferents also respond to low-pressure
the thoracic (T1-T3) spinal cord distention and innocuous
tract)

PT
chemostimulation
Chemoreceptor trigger zone;
AP neurons innervate the NTS;
Dorsal to the NTS, adjacent to Contain receptors for, and respond to, a
Area postrema NTS and DMV neuronal

RI
the 4th ventricle variety of circulating factors including
dendrites reach the AP
immune and inflammatory mediators
Midbrain

SC
Reciprocal connections with DVC
Paraventricular nucleus Hypothalamus; adjacent to 3rd ; release neurotransmitters into Stress-induced GI responses, including
of the hypothalamus ventricle within periventricular
neurohypophysis and hormones arousal, anxiety and depression

U
(PVN) zone into hypophysial portal system;

AN
Hypothalamus; adjacent to the Integration of endocrine and behavioral
Arcuate nucleus (Arc) 3rd ventricle, in close apposition Reciprocal connections with DVC aspects of GI functions
to median eminence Modulation of food intake and satiety

M
Receives inputs from NTS Regulation of bladder and colon function;
Barrington’s nucleus Dorsolateral pons assimilation of emotional and cognitive
behaviors with GI functions

D
Surrounds cerebral aqueduct
Periaqueductal gray Integration of fear and anxiety; pain
from dorsal tegmental nucleus Dense innervation from NTS

TE
(PAG) to posterior commissure modulation
A6 noradrenergic region; Maintenance of arousal and attention;
Locus coeruleus (LC) located at rostral pons at lateral Reciprocal connections with DVC integration of emotional responses and
EP
floor of 4th ventricle cognitive inputs with GI functions; stress
Forebrain
Learning and memory; integrative of
C

Central nucleus of the Heterogeneous complex within emotional and aversive inputs with
AC

Reciprocal connections with DVC learning, memory and autonomic GI

amygdala (CeA) anteromedial temporal lobe
functions; prominent role in anxiety and
stress-related GI disorders
Bed Nucleus of the Stria Processing and consolidation of behavior
Part of the extended amygdala Reciprocal connections with DVC and emotions; regulation of HPA axis and
Terminalis (BNST) autonomic (GI) responses to stress
Direct descending connections
(infralimbic and prelimbic cortex)
Cortex to DVC; indirect descending Integration of affect, emotion and memory
with autonomic (GI) functions
connections via hypothalamus
and amygdala
 ACCEPTED MANUSCRIPT

PT
RI
U SC
AN
M
D
TE
EP
C
AC
 ACCEPTED MANUSCRIPT

PT
RI
U SC
AN
M
D
TE
EP
C
AC